Breast Milk News and Research

RSS

FDA approves BOTOX as prophylactic treatment for Chronic Migraine

Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved BOTOX(onabotulinumtoxinA) for the prophylactic (preventive) treatment of headaches in adults with Chronic Migraine.

18 Oct 2010

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced the launch of My SPRYCEL (dasatinib) Support, a useful resource to assist adult patients with chronic myeloid leukemia (CML) who are taking SPRYCEL.

15 Oct 2010

International experts to discuss effect of diet on children's mental and behavioral development

Can diet affect our children's long-term mental and behavioural development. This question will be addressed by a number of international leading experts on child nutrition next 6th of October in York, at a public event organized within the 7th Framework Programme Nutrimenthe, entitled "Effect of diet on the mental performance of children".

5 Oct 2010

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.

4 Oct 2010

Consumption of diet high in trans fats by mothers doubles risk of high body fat levels in infants

A new University of Georgia study suggests that mothers who consume a diet high in trans fats double the likelihood that their infants will have high levels of body fat.

30 Sep 2010

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds outperformed market leader Roche's drug Ganciclovir in cell culture and plaque reduction assay (the gold standard) for Cytomegalovirus (CMV) disease. Additionally, antiviral activity was also apparent against other human herpesviruses, namely, HSV-1 (cold sores), HSV-2 (genital herpes), and Varicella-Zoster Virus (VZV) (chicken-pox and shingles).

29 Sep 2010

Prescription only baby formula proposal

It has been known and recommended for some time now that breast milk is the best food for a new born. However for mothers who cannot breast feed, this has been a serious issue related to guilt and anguish. The controversy took a new turn as a Melbourne doctor of midwifery called for infant formula to be made available only by prescription. RMIT University expert Dr Jennifer James wants infant formula banned from supermarket shelves.

23 Sep 2010

Chemicals in non-stick cookware elevates cholesterol level among children: Report

Children and teens with higher blood levels of chemicals used in the production of non-stick cookware and waterproof fabrics appear more likely to have elevated total and LDL cholesterol levels, according to a report in the September issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

7 Sep 2010

Four week old children being fed a poor diet of biscuits, ice-cream and soft drinks

Children as young as four weeks old are being fed a poor diet of biscuits, ice-cream and soft drinks, according to new Australian research.

6 Sep 2010

Study finds high content of aluminium in infant formulas

The aluminium content of a range of the most popular brands of infant formulas remains high, and particularly so for a product designed for preterm infants and a soya-based product designed for infants with cow's milk intolerances and allergies, researchers have found.

3 Sep 2010

Vitamin A and beta-carotene supplements unsafe for HIV-positive women

Vitamin A and beta-carotene supplements are unsafe for HIV-positive women who breastfeed because they may boost the excretion of HIV in breast milk---thereby increasing the chances of transmitting the infection to the child, a pair of new studies suggest.

27 Aug 2010

Lysozyme can protect anthrax contamination in processed foods: Study

An antibacterial enzyme found in human tears and other body fluids could be applied to certain foods for protection against intentional contamination with anthrax, scientists reported here today at the 240th National Meeting of the American Chemical Society (ACS).

27 Aug 2010

Vitamin A may boost HIV excretion in breast milk: Study

Vitamin A and beta-carotene supplements are unsafe for HIV-positive women who breastfeed because they may boost the excretion of HIV in breast milk thereby increasing the chances of transmitting the infection to the child, a pair of new studies suggest.

26 Aug 2010

Sea food for babies

Has your toddler eaten fish today? A University of Illinois food science professor has two important reasons for including seafood in your young child's diet, reasons that have motivated her work in helping to develop a tasty, nutritious salmon baby food for toddlers.

25 Aug 2010

Agilent's HPLC-Chip/MS technology helps identify over 200 different human milk oligosaccharides structures

Agilent Technologies Inc. today announced that a group of researchers from the University of California, Davis, has made a significant discovery: human breast milk contains an unexpected abundance of sugars that coats the lining of infants' intestines, protecting it from noxious bacteria. Results of the research, which used Agilent technology, were published in this month's Proceedings of the National Academy of Sciences of the United States of America.

18 Aug 2010

Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting

New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a favorable benefit-risk profile for up to three years of treatment, consistent with previous analyses.

10 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

FSU biologist-mathematician team receives $2.64 million grant to study prolactin secretion

A Florida State University biologist and mathematician have joined forces to find out exactly how the brain oversees the secretion of the hormone prolactin from the pituitary gland, research that could lead to new ways to treat hundreds of disorders, including infertility.

4 Aug 2010

Ten steps to successful breastfeeding from WHO and UNICEF

During World Breastfeeding Week, celebrated from 1 to 7 August in more than 170 countries, WHO reiterates its call on health facilities and health workers to implement ten steps to help mothers breastfeed successfully and improve their babies' health and chances of survival.

30 Jul 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010